SUPPLEMENT APPROVAL

NDA 21752/S-035

Gilead Sciences, Inc.
Attention: Andrea Canavero
Associate Manager, Regulatory Affairs
333 Lakeside Drive
Foster City, CA 94404

Dear Ms. Canavero:

Please refer to your Supplemental New Drug Application (sNDA) dated December 17, 2012, received December 18, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Truvada (emtricitabine/tenofovir disoproxil fumarate) tablets, 200 mg and 300 mg.


This “Prior Approval” supplemental new drug application proposes to add STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) to the list of drugs not to be coadministered with Truvada (emtricitabine/tenofovir disoproxil fumarate) tablets in the Indications and Usage and Warnings and Precautions sections of the Full Prescribing Information (PI) and the Medication Guide, as well as to update the Drug Interactions and Pediatric Use sections of the PI.

This supplemental new drug application also proposes modifications to the approved risk evaluation and mitigation strategy (REMS).

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Reference ID: 3325780
Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Truvada (emtricitabine/tenofovir disoproxil fumarate) tablets was originally approved on July 16, 2012. The REMS consists of a Medication Guide, elements to assure safe use, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist(s) of minor text revisions to the REMS materials including the Medication Guide, the Uninfected Individuals Safety Brochure, the Prescriber Safety Brochure and the Training Guide for Healthcare Providers to incorporate the following change to the Prescribing Information: the addition of STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) to the list of drugs not to be coadministered with Truvada (emtricitabine/tenofovir disoproxil fumarate) tablets.

Your proposed modified REMS, submitted on May 30, 2013, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS will remain the same as that approved on July 16, 2012.

There are no changes to the REMS assessment plan described in our July 16, 2012 letter.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA.
If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

NDA 21752 REMS CORRESPONDENCE
(insert concise description of content in bold capital letters, e.g.,
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY)

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 21752 REMS ASSESSMENT
NEW SUPPLEMENT FOR NDA 21752
PROPOSED REMS MODIFICATION
NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 21752
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/opacom/morechoices/fdaforms/cder.html](http://www.fda.gov/opacom/morechoices/fdaforms/cder.html); instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Katherine Schumann, M.S., Regulatory Project Manager, at (301) 796-1182 or the Division’s main number at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Kendall A. Marcus, M.D.
Deputy Director for Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

**ENCLOSURES:**

- Content of Labeling
- REMS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
06/17/2013